Search Bar & Filters
Found 101 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments to prevent non-small cell lung cancer NSCLC from returning after surgery in people with high-risk, localized Stage I NSCLC. This Phase 3 randomized clinical trial compares adjuvant intismeran autogene V940 alone or combined with subcutaneous pembrolizumab and berahyaluronidase alfa against placebo in participants who have had their cancer completely removed. The goal is to improve disease-free survival in these patients. Participants are assigned to one of three groups one receives intismeran 1 mg by intramuscular injection plus pembrolizumab with berahyaluronidase alfa by subcutaneous injection another group receives intismeran alone by intramuscular injection and the third group receives a placebo injection. Treatments are given as part of the study, with dosing schedules and combinations designed to evaluate their effects on cancer recurrence. During the study, participants will be closely monitored through regular assessments including imaging scans and laboratory tests to track disease status and side effects. Researchers will measure outcomes such as disease-free survival, distant metastasis-free survival, overall survival, and quality of life using standardized questionnaires. Safety will also be monitored throughout the study, which may last up to several years for some participants.
Actively Recruiting
Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are studying pacing-induced cardiomyopathy PICM, a condition where chronic right ventricular pacing harms left ventricular function. This observational study focuses on ECG and echocardiogram parameters, including strain, as well as genetic factors, to identify patients at high risk of developing PICM after pacemaker implantation. The goal is to better predict who might develop PICM and understand its clinical impact over time. Participants will have ECG and echocardiogram tests before and after pacemaker implantation to assess key measurements such as QRS duration and mechanical strain. Genetic factors may also be evaluated to improve prediction of PICM occurrence. This study involves long-term follow-up to monitor the condition and its outcomes. During the study, participants will be clinically followed for up to 5 years to observe heart failure diagnosis and treatment. Researchers will also track atrial and ventricular arrhythmias, hospital admissions for heart failure, and overall mortality. The study does not involve treatment interventions but focuses on monitoring and data collection to understand PICM and its clinical outcomes.
Actively Recruiting
Healthy Volunteer
This trial investigates the safety and drug-drug interaction between DW4421 and three different nonsteroidal anti-inflammatory drugs NSAIDs in healthy adult volunteers. The study is a Phase 1 clinical trial designed to assess how these drugs interact in the body, focusing on their pharmacokinetics, which helps understand the drug levels and behavior over time. Participants will receive different forms of the investigational drug DW4421, administered once daily or twice daily depending on the variant DW4421, DW4421-N1, DW4421-N2, DW4421-N3. The study is randomized and includes several cohorts to evaluate these combinations carefully. Each participant will follow specific dosing schedules during the trial. During the trial, researchers will monitor participants closely through various assessments including measuring drug concentration peaks Cmax and overall exposure AUC from baseline to study days 13 or 15. Healthy volunteers aged 19 to 50 will be observed for any safety concerns or changes in how the drugs work together. The total study participation lasts from the start until the final assessments around day 15, with continuous monitoring of drug interactions and safety.
Actively Recruiting
Researchers are evaluating the safety, tolerability, how the body processes and responds to BGB-B2033, and its preliminary antitumor activity in adults with advanced or metastatic cancers including hepatocellular carcinoma, alpha-fetoprotein-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, and glypican-3-positive squamous non-small cell lung cancer. The study aims to find the recommended dose for further research when BGB-B2033 is given alone or combined with tislelizumab, with or without bevacizumab. Participants will receive BGB-B2033 through intravenous infusion either alone or combined with tislelizumab and sometimes bevacizumab. The study includes several parts dose escalation and safety expansion of BGB-B2033 alone, combination treatments to determine safe doses and recommended doses for expansion, and dose expansion in specific groups including participants with hepatocellular carcinoma in Asia and the United States. During the study, participants will have regular assessments to monitor safety, side effects, how their body processes BGB-B2033, and whether their cancer responds to treatment. Researchers will track adverse events, the best dose, overall response rates, duration of response, disease control, progression-free survival, serum drug levels, and overall survival for up to about two years. Participants will be closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating JIN-A02, a fourth-generation EGFR-TKI oral medication, in people with advanced non-small cell lung cancer NSCLC that has specific EGFR mutations and has progressed after standard treatments. This Phase III open-label study focuses on assessing the safety, tolerability, pharmacokinetics, and anti-tumor activity of JIN-A02 in those who have previously received approved EGFR-TKI therapy andor platinum-based chemotherapy. The study includes multiple parts to explore dosing and treatment effects based on mutation types. The study has three parts Part A is a dose escalation phase using a Bayesian Optimal Interval design to find the maximum tolerated dose MTD in patients with EGFR mutations C797S or T790M. JIN-A02 is given once daily in 28-day cycles, with dose adjustments based on safety evaluations. Part B further explores two selected dose levels to determine the recommended Phase 2 dose RP2D. Part C expands treatment to five cohorts defined by specific EGFR mutation profiles, monitoring anti-tumor activity using the established RP2D. Participants undergo regular assessments including safety reviews by a committee, tumor mutation testing from tissue or plasma samples, and monitoring for adverse events and dose-limiting toxicities. The study measures outcomes such as maximum tolerated dose, adverse event rates, and dose-limiting toxicities over specified timeframes. The study duration and follow-up depend on the dose-escalation, exploration, and expansion phases with ongoing data collection for safety and benefit-risk analysis.
Actively Recruiting
Researchers are evaluating YH42946, a new oral drug that targets HER2 abnormalities and EGFR exon 20 insertions, in patients with locally advanced or metastatic solid tumors. This Phase 12, open-label, multicenter study aims to assess the safety, tolerability, how the drug moves through the body, and anti-tumor activity of YH42946. The study involves patients who have progressed after standard treatments or for whom standard therapy is not suitable. The study has two parts the first part involves gradually increasing doses to find the highest safe dose. The second part expands dosing to select recommended doses for further evaluation. Several independent patient groups are planned. Participants receive YH42946 orally as the investigational treatment. Participants will be closely monitored through clinical assessments, laboratory tests, and imaging to evaluate safety and tumor response. Researchers will measure treatment emergent adverse events during the initial 21 days and objective tumor response over approximately 12 months. Pharmacokinetic analyses will assess drug absorption and metabolism throughout the study. Participation may last up to about one year, including follow-up evaluations.
Actively Recruiting
Researchers are evaluating HMBD-001, an anti-HER3 antibody, in combination with cetuximab with or without docetaxel for people with advanced squamous cell cancers. This Phase IbII, open-label, multi-center study focuses on various types of advanced or metastatic squamous cell carcinomas, including lung, head and neck, esophageal, cervical, cutaneous, and nasopharyngeal cancers. The study aims to assess the safety and effectiveness of these treatments in participants who have limited standard care options. Participants receive HMBD-001 intravenously once a week alongside cetuximab weekly, with or without docetaxel administered every three weeks. There are three treatment arms one with HMBD-001 plus docetaxel, one with HMBD-001 plus docetaxel and cetuximab both closed to recruitment, and one with HMBD-001 plus cetuximab. The trial evaluates different combinations to understand their effects on advanced squamous cell cancers. During the study, participants are monitored for adverse events and dose-limiting toxicities. Researchers track progression-free survival up to six months and measure tumor response using established criteria. Blood samples are collected to study the drugs behavior in the body and immune response. The study includes repeated treatment cycles and safety follow-up, with assessments continuing up to 48 months. Participants undergo tumor biopsies and organ function tests to ensure safety and gather comprehensive data.
Actively Recruiting
Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.
1-10 of 101
1